Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices

References

• Abd Elwakil MM, Mabrouk MT, Helmy MW, et al. (2018). Inhalable lactoferrin–chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma. Nanomedicine 13:2015–35.
   PubMed Web of Science ®Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. (2018). Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release 269:374–92.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Akhter S, Rizwanullah M, et al. (2015). Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci Appl 8:55–66.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Khedr A, Atteiah SG, Al-Abbasi FA. (2020). Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug. Saudi Pharm J 28:754–62.
   PubMed Web of Science ®Google Scholar
• Alipour S, Montaseri H, Tafaghodi M. (2010). Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids Surf B Biointerfaces 81:521–9.
   PubMed Web of Science ®Google Scholar
• Anderson CF, Grimmett ME, Domalewski CJ, Cui H. (2020). Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12:e1586.
   PubMed Web of Science ®Google Scholar
• Arneth B. (2020). Tumor microenvironment. Medicina 56:15.
   Google Scholar
• Asamura H, Chansky K, Crowley J, et al. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675–84.
   PubMed Web of Science ®Google Scholar
• Barta JA, Powell CA, Wisnivesky JP. (2019). Global epidemiology of lung cancer. Ann Glob Health 85:8.
   PubMed Web of Science ®Google Scholar
• Beola L, Asín L, Fratila RM, et al. (2018). Dual role of magnetic nanoparticles as intracellular hotspots and extracellular matrix disruptors triggered by magnetic hyperthermia in 3D cell culture models. ACS Appl Mater Interfaces 10:44301–13.
   PubMed Web of Science ®Google Scholar
• Bianchi A, Dufort S, Lux F, et al. (2014). Targeting and in vivo imaging of non-small-cell lung cancer using nebulized multimodal contrast agents. Proc Natl Acad Sci USA 111:9247–52.
   PubMed Web of Science ®Google Scholar
• Board PATE. Non-small cell lung cancer treatment (PDQ®). PDQ cancer information summaries [Internet]. US: National Cancer Institute; 2020.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
   PubMed Web of Science ®Google Scholar
• Chaurasiya B, Zhao Y-Y. (2021). Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics 13:31.
   Web of Science ®Google Scholar
• Chen J, Yang X, Huang L, et al. (2018). Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy. Drug Deliv 25:1932–42.
   PubMed Web of Science ®Google Scholar
• Chen R, Manochakian R, James L, et al. (2020). Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol 13:58.
   PubMed Web of Science ®Google Scholar
• Cheng B, Xiong S, Li C, et al. (2020). An annual review of the remarkable advances in lung cancer clinical research in 2019. J Thorac Dis 12:1056–69.
   PubMed Web of Science ®Google Scholar
• Choi SH, Byeon HJ, Choi JS, et al. (2015). Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 197:199–207.
   PubMed Web of Science ®Google Scholar
• Cidem A, Bradbury P, Traini D, Ong HX. (2020). Modifying and integrating in vitro and ex vivo respiratory models for inhalation drug screening. Front Bioeng Biotechnol 8:581995.
   PubMed Web of Science ®Google Scholar
• Clegg A, Scott D, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Database of Abstracts of Reviews of Effects (DARE): quality-assessed reviews [Internet]. UK: Centre for Reviews and Dissemination; 2001.
   Google Scholar
• Danhier F. (2016). To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244:108–21.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Miller KD, Goding Sauer A, et al. (2019). Cancer statistics for African Americans, 2019. CA A Cancer J Clin 69:211–33.
   PubMed Web of Science ®Google Scholar
• Di Pietro P, Zaccaro L, Comegna D, et al. (2016). Silver nanoparticles functionalized with a fluorescent cyclic RGD peptide: a versatile integrin targeting platform for cells and bacteria. RSC Adv 6:112381–92.
   Web of Science ®Google Scholar
• Dufort S, Bianchi A, Henry M, et al. (2015). Nebulized gadolinium-based nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization. Small 11:215–21.
   PubMed Web of Science ®Google Scholar
• Dusinska M, Tulinska J, El Yamani N, et al. (2017). Immunotoxicity, genotoxicity and epigenetic toxicity of nanomaterials: new strategies for toxicity testing? Food Chem Toxicol 109:797–811.
   PubMed Web of Science ®Google Scholar
• Escobar-Chávez JJ, Díaz-Torres R, Rodríguez-Cruz IM, et al. (2012). Nanocarriers for transdermal drug delivery. Res Rep Transdermal Drug Deliv 1:3–17.
   Google Scholar
• Fares J, Fares MY, Khachfe HH, et al. (2020). Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5:28.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. (2009). Impact of nanotechnology on drug delivery. ACS Nano 3:16–20.
   PubMed Web of Science ®Google Scholar
• Felfoul O, Mohammadi M, Taherkhani S, et al. (2016). Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nat Nanotechnol 11:941–7.
   PubMed Web of Science ®Google Scholar
• Gadoue SM, Toomeh D. (2019). Radio-sensitization efficacy of gold nanoparticles in inhalational nanomedicine and the adverse effect of nano-detachment due to coating inactivation. Phys Med 60:7–13.
   PubMed Web of Science ®Google Scholar
• Gagnadoux F, Hureaux J, Vecellio L, et al. (2008). Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 21:61–70.
   PubMed Web of Science ®Google Scholar
• Ganipineni LP, Ucakar B, Joudiou N, et al. (2019). Paclitaxel-loaded multifunctional nanoparticles for the targeted treatment of glioblastoma. J Drug Target 27:614–23.
   PubMed Web of Science ®Google Scholar
• Gaspar R, Duncan R. (2009). Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 61:1220–31.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Han G, De M, et al. (2008). Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60:1307–15.
   PubMed Web of Science ®Google Scholar
• Gill KK, Nazzal S, Kaddoumi A. (2011). Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 79:276–84.
   PubMed Web of Science ®Google Scholar
• Godugu C, Patel AR, Doddapaneni R, et al. (2013). Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release 172:86–95.
   PubMed Web of Science ®Google Scholar
• Hamzawy MA, Abo-Youssef AM, Salem HF, Mohammed SA. (2017). Antitumor activity of intratracheal inhalation of temozolomide (TMZ) loaded into gold nanoparticles and/or liposomes against urethane-induced lung cancer in BALB/c mice. Drug Deliv 24:599–607.
   PubMed Web of Science ®Google Scholar
• Haque S, Whittaker M, McIntosh MP, et al. (2018). A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. Eur J Pharm Biopharm 125:1–12.
   PubMed Web of Science ®Google Scholar
• Haume K, Rosa S, Grellet S, et al. (2016). Gold nanoparticles for cancer radiotherapy: a review. Cancer Nanotechnol 7:8–20.
   PubMedGoogle Scholar
• He B, Sui X, Yu B, et al. (2020). Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Deliv 27:1474–90.
   PubMed Web of Science ®Google Scholar
• Hershey AE, Kurzman ID, Forrest LJ, et al. (1999). Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 5:2653–9.
   PubMed Web of Science ®Google Scholar
• Herter-Sprie GS, Korideck H, Christensen CL, et al. (2014). Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat Commun 5:5870–8.
   PubMed Web of Science ®Google Scholar
• Hickey AJ. (2020). Emerging trends in inhaled drug delivery. Adv Drug Deliv Rev 157:63–70.
   PubMed Web of Science ®Google Scholar
• Hirsch F, Varella-Garcia M, Cappuzzo F. (2009). Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28(Suppl 1):S32–S7.
   PubMedGoogle Scholar
• Hoffman AS. (2013). Stimuli-responsive polymers: biomedical applications and challenges for clinical translation. Adv Drug Deliv Rev 65:10–6.
   PubMed Web of Science ®Google Scholar
• Hollis CP, Weiss HL, Evers BM, et al. (2014). In vivo investigation of hybrid paclitaxel nanocrystals with dual fluorescent probes for cancer theranostics. Pharm Res 31:1450–9.
   PubMed Web of Science ®Google Scholar
• Hollis CP, Weiss HL, Leggas M, et al. (2013). Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release 172:12–21.
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Shibuya M, Niho S, et al. (2011). Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res 31:3449–56.
   PubMed Web of Science ®Google Scholar
• Hu L, Jia Y. (2010). Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Die Pharm 65:585–7.
   PubMed Web of Science ®Google Scholar
• Islam N, Richard D. (2019). Inhaled micro/nanoparticulate anticancer drug formulations: an emerging targeted drug delivery strategy for lung cancers. Curr Cancer Drug Targets 19:162–78.
   PubMed Web of Science ®Google Scholar
• Jin X, Song L, Ma C-C, et al. (2020). Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases. Saudi Pharm J 28:1655–65.
   PubMed Web of Science ®Google Scholar
• Joshi N, Shirsath N, Singh A, et al. (2014). Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep 4:7085–11.
   PubMed Web of Science ®Google Scholar
• Jyoti K, Kaur K, Pandey RS, et al. (2015). Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies. J Colloid Interface Sci 445:219–30.
   PubMed Web of Science ®Google Scholar
• Kabary DM, Helmy MW, Abdelfattah E-ZA, et al. (2018). Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma. Eur J Pharm Biopharm 130:152–64.
   PubMed Web of Science ®Google Scholar
• Kadam AN, Najlah M, Wan K-W, et al. (2014). Stability of parenteral nanoemulsions loaded with paclitaxel: the influence of lipid phase composition, drug concentration and storage temperature. Pharm Dev Technol 19:999–1004.
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, McLeod VM, Ryan GM, et al. (2014). Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release 183:18–26.
   PubMed Web of Science ®Google Scholar
• Karra N, Nassar T, Laenger F, et al. (2013). Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model. Curr Cancer Drug Targets 13:11–29.
   PubMed Web of Science ®Google Scholar
• Katsurada N, Tachihara M, Hatakeyama Y, et al. (2020). Feasibility study of adjuvant chemotherapy with carboplatin and nab-paclitaxel for completely resected NSCLC. Cancer Manag Res 12:777–82.
   PubMed Web of Science ®Google Scholar
• Keith RL, Miller YE, Gemmill RM, et al. (2000). Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 6:1616–25.
   PubMed Web of Science ®Google Scholar
• Kim I, Byeon HJ, Kim TH, et al. (2013). Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials 34:6444–53.
   PubMed Web of Science ®Google Scholar
• Kolosnjaj-Tabi J, Marangon I, Nicolas-Boluda A, et al. (2017). Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix. Pharmacol Res 126:123–37.
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Waldrep JC, Roberts LE, et al. (2001). Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–62.
   PubMed Web of Science ®Google Scholar
• Kumar A, Dailey LA, Forbes B. (2014). Lost in translation: what is stopping inhaled nanomedicines from realizing their potential? Ther Deliv 5:757–61.
   PubMedGoogle Scholar
• Kumar R, Korideck H, Ngwa W, et al. (2013). Third generation gold nanoplatform optimized for radiation therapy. Transl Cancer Res 2.
   Google Scholar
• Kuribayashi K, Funaguchi N, Nakano T. (2016). Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. J Cancer Res Ther 12:528–34.
   PubMed Web of Science ®Google Scholar
• Kuzmov A, Minko T. (2015). Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 219:500–18.
   PubMed Web of Science ®Google Scholar
• Labiris N, Dolovich M. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588–99.
   PubMed Web of Science ®Google Scholar
• Lakkadwala S, Nguyen S, Nesamony J, et al. Smart polymers in drug delivery. Excipient applications in formulation design and drug delivery. Springer, Cham, Switzerland;2015. p. 169–99.
   Google Scholar
• Lee W-H, Loo C-Y, Ghadiri M, et al. (2018). The potential to treat lung cancer via inhalation of repurposed drugs. Adv Drug Deliv Rev 133:107–30.
   PubMed Web of Science ®Google Scholar
• Lee W-H, Loo C-Y, Traini D, Young PM. (2015). Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges. Asian J Pharm Sci 10:481–9.
   Web of Science ®Google Scholar
• Lemarie E, Vecellio L, Hureaux J, et al. (2011). Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv 24:261–70.
   PubMed Web of Science ®Google Scholar
• Li G, Wang S, Deng D, et al. (2020). Fluorinated chitosan to enhance transmucosal delivery of sonosensitizer-conjugated catalase for sonodynamic bladder cancer treatment post-intravesical instillation. ACS Nano 14:1586–99.
   PubMed Web of Science ®Google Scholar
• Li W, Zhan P, De Clercq E, et al. (2013). Current drug research on PEGylation with small molecular agents. Prog Polym Sci 38:421–44.
   Web of Science ®Google Scholar
• Li Z, Shan X, Chen Z, et al. (2020). Applications of surface modification technologies in nanomedicine for deep tumor penetration. Adv Sci 8:2002589.
   Web of Science ®Google Scholar
• Liang X, Ye X, Wang C, et al. (2019). Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release 296:150–61.
   PubMed Web of Science ®Google Scholar
• Lim SH, Kathuria H, Tan JJY, Kang L. (2018). 3D printed drug delivery and testing systems – a passing fad or the future? Adv Drug Deliv Rev 132:139–68.
   PubMed Web of Science ®Google Scholar
• Liu JF, Lan Z, Ferrari C, et al. (2020). Use of oppositely polarized external magnets to improve the accumulation and penetration of magnetic nanocarriers into solid tumors. ACS Nano 14:142–52.
   PubMed Web of Science ®Google Scholar
• Liu M, Du H, Zhang W, Zhai G. (2017). Internal stimuli-responsive nanocarriers for drug delivery: design strategies and applications. Mater Sci Eng C Mater Biol Appl 71:1267–80.
   PubMed Web of Science ®Google Scholar
• Liyanage PY, Hettiarachchi SD, Zhou Y, et al. (2019). Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer 1871:419–33.
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207.
   PubMedGoogle Scholar
• Mangal S, Gao W, Li T, Zhou QT. (2017). Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin 38:782–97.
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Veslemes M, Kouroussis C, et al. (2002). Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung Cancer 38:59–63.
   PubMed Web of Science ®Google Scholar
• Mazzotta E, De Benedittis S, Qualtieri A, Muzzalupo R. (2020). Actively targeted and redox responsive delivery of anticancer drug by chitosan nanoparticles. Pharmaceutics 12:26.
   Web of Science ®Google Scholar
• McBride AA, Price DN, Lamoureux LR, et al. (2013). Preparation and characterization of novel magnetic nano-in-microparticles for site-specific pulmonary drug delivery. Mol Pharm 10:3574–81.
   PubMed Web of Science ®Google Scholar
• Menon JU, Kuriakose A, Iyer R, et al. (2017). Dual-drug containing core-shell nanoparticles for lung cancer therapy. Sci Rep 7:13249–13.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Rosenbaum AS. (1967). The vascular supply to metastatic tumors of lung. Surg Gynecol Obstet 125:1009–12.
   PubMedGoogle Scholar
• Miller MA, Chandra R, Cuccarese MF, et al. (2017). Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med 9:eaal0225.
   PubMed Web of Science ®Google Scholar
• Milne EN, Noonan CD, Margulis AR, Stoughton JA. (1969). Vascular supply of pulmonary metastases: experimental study in rats. Invest Radiol 4:215–29.
   PubMed Web of Science ®Google Scholar
• Mishra B, Singh J. Novel drug delivery systems and significance in respiratory diseases. Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Elsevier; Cambridge, MA, USA, 2020. p. 57–95.
   Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318.
   PubMed Web of Science ®Google Scholar
• Mottaghitalab F, Farokhi M, Fatahi Y, et al. (2019). New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J Control Release 295:250–67.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 50:161–77.
   PubMed Web of Science ®Google Scholar
• Nan Y. (2019). Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. Oncol Rep 42:2087–96.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Kumar R, Moreau M, et al. (2017). Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids. Front Oncol 7:208.
   PubMed Web of Science ®Google Scholar
• Okuda T, Okamoto H. (2020). Present situation and future progress of inhaled lung cancer therapy: necessity of inhaled formulations with drug delivery functions. Chem Pharm Bull 68:589–602.
   PubMed Web of Science ®Google Scholar
• Pancewicz-Wojtkiewicz J. (2016). Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. Cancer Med 5:3572–8.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329–47.
   PubMed Web of Science ®Google Scholar
• Patil J, Sarasija S. (2012). Pulmonary drug delivery strategies: a concise, systematic review. Lung India 29:44–9.
   PubMedGoogle Scholar
• Patra JK, Das G, Fraceto LF, et al. (2018). Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 16:71.
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. (2015). Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79.
   PubMed Web of Science ®Google Scholar
• Pontes JF, Grenha A. (2020). Multifunctional nanocarriers for lung drug delivery. Nanomaterials 10:183.
   Web of Science ®Google Scholar
• Pucci C, Martinelli C, Ciofani G. (2019). Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 13:961.
   PubMed Web of Science ®Google Scholar
• Rejman J, Oberle V, Zuhorn IS, Hoekstra D. (2004). Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377:159–69.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Fallah M, et al. (2014). Metastatic sites and survival in lung cancer. Lung Cancer 86:78–84.
   PubMed Web of Science ®Google Scholar
• Roa WH, Azarmi S, Al-Hallak MK, et al. (2011). Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 150:49–55.
   PubMed Web of Science ®Google Scholar
• Rodríguez ML, Padellano LC. (2007). Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Transl Oncol 9:506–12.
   PubMed Web of Science ®Google Scholar
• Rosière R, Amighi K, Wauthoz N. Nanomedicine-based inhalation treatments for lung cancer. Nanotechnology-based targeted drug delivery systems for lung cancer. Elsevier; Cambridge, MA, USA, 2019. p. 249–68.
   Google Scholar
• Rosiere R, Van Woensel M, Gelbcke M, et al. (2018). New folate-grafted chitosan derivative to improve delivery of paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation. Mol Pharm 15:899–910.
   PubMed Web of Science ®Google Scholar
• Ruge CA, Kirch J, Lehr C-M. (2013). Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic possibilities and technological challenges. Lancet Respir Med 1:402–13.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Kim K, Hutson P, et al. (1996). Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14:2345–52.
   PubMed Web of Science ®Google Scholar
• Schreier H, Gagné L, Bock T, et al. (1997). Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes. Pharm Acta Helv 72:215–23.
   PubMedGoogle Scholar
• Senapati S, Mahanta AK, Kumar S, Maiti P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 3:7–19.
   PubMed Web of Science ®Google Scholar
• Seynhaeve A, Amin M, Haemmerich D, et al. (2020). Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv Drug Deliv Rev 163–164:125–44.
   PubMed Web of Science ®Google Scholar
• Sharma S, White D, Imondi AR, et al. (2001). Development of inhalational agents for oncologic use. J Clin Oncol 19:1839–47.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer statistics. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Silva CO, Pinho JO, Lopes JM, et al. (2019). Current trends in cancer nanotheranostics: metallic, polymeric, and lipid-based systems. Pharmaceutics 11:22.
   PubMed Web of Science ®Google Scholar
• Smulders S, Ketkar-Atre A, Luyts K, et al. (2016). Body distribution of SiO2-Fe3O4 core–shell nanoparticles after intravenous injection and intratracheal instillation. Nanotoxicology 10:567–74.
   PubMed Web of Science ®Google Scholar
• Song G, Cheng L, Chao Y, et al. (2017). Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater 29:1700996.
   Web of Science ®Google Scholar
• Spiro SG, Porter JC. (2002). Lung cancer—where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166:1166–96.
   PubMed Web of Science ®Google Scholar
• Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. (2019). Gold nanoparticles in cancer treatment. Mol Pharm 16:1–23.
   PubMed Web of Science ®Google Scholar
• Takashima S, Imai K, Atari M, et al. (2020). Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study. World J Surg Oncol 18:263–9.
   PubMed Web of Science ®Google Scholar
• Taratula O, Garbuzenko OB, Chen AM, Minko T. (2011). Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 19:900–14.
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, et al. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 171:349–57.
   PubMed Web of Science ®Google Scholar
• The American Cancer Society; 2021. Available from: https://cancerstatisticscenter.cancer.org/?_ga=2.236451137.1376254229.1599038689-1856180511.1598119698%20-%20!/#!/
   Google Scholar
• Torrico-Guzman EA, Meenach S, editors. Tumor-penetrating aerosol nanocomposite microparticles for the treatment of lung cancer. 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC). IEEE; 2015.
   Google Scholar
• Tseng C-L, Su W-Y, Yen K-C, et al. (2009). The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30:3476–85.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Hassanzadeh F, Mardani A, Rostami M. (2015). Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery. Pharm Dev Technol 20:183–96.
   PubMed Web of Science ®Google Scholar
• Verbanck S, Biddiscombe MF, Usmani OS. (2020). Inhaled aerosol dose distribution between proximal bronchi and lung periphery. Eur J Pharm Biopharm 152:18–22.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Gilbert BE, Loyer E, et al. (2004). Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10:2319–26.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Tepper JE. (2014). Nanotechnology in radiation oncology. J Clin Oncol 32:2879–85.
   PubMed Web of Science ®Google Scholar
• Wang CE, Yumul RC, Lin J, et al. (2018). Junction opener protein increases nanoparticle accumulation in solid tumors. J Control Release 272:9–16.
   PubMed Web of Science ®Google Scholar
• Wang X, Luo J, He L, et al. (2018). Hybrid pH-sensitive nanogels surface-functionalized with collagenase for enhanced tumor penetration. J Colloid Interface Sci 525:269–81.
   PubMed Web of Science ®Google Scholar
• Wittgen BP, Kunst PW, Van Der Born K, et al. (2007). Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 13:2414–21.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang Y, Guo Z, et al. (2019). Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J Control Release 295:153–63.
   PubMed Web of Science ®Google Scholar
• Yan L, Shen J, Wang J, et al. (2020). Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose Response 18:1559325820936161.
   Web of Science ®Google Scholar
• Yıldız-Peköz A, Ehrhardt C. (2020). Advances in pulmonary drug delivery. Pharmaceutics 12:911.
   Google Scholar
• Yuan M, Huang L-L, Chen J-H, et al. (2019). The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 4:61–14.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Chatzaki E, Porpodis K, et al. (2012). Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine 7:1551–72.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Eleftheriadou E, Zarogoulidou V, et al. (2010). Feasibility and effectiveness of inhaled carboplatin in the treatment of NSCLC patients. J Clin Oncol 28:e17511.
   Web of Science ®Google Scholar
• Zhang F, Lu G, Wen X, et al. (2020). Magnetic nanoparticles coated with polyphenols for spatio-temporally controlled cancer photothermal/immunotherapy. J Control Release 326:131–9.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hollis CP, Zhang Q, Li T. (2011). Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm 415:293–300.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu L, Chan H-K, Watanabe W. (2011). Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 63:441–55.
   PubMed Web of Science ®Google Scholar
• Zhong Q, Humia BV, Punjabi AR, et al. (2017). The interaction of dendrimer–doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers. Eur J Pharm Sci 109:86–95.
   PubMed Web of Science ®Google Scholar
• Zhong Q. (2018). Co-spray dried mannitol/poly(amidoamine)–doxorubicin dry-powder inhaler formulations for lung adenocarcinoma: morphology, in vitro evaluation, and aerodynamic performance. AAPS PharmSciTech 19:531–40.
   PubMed Web of Science ®Google Scholar
• Zou Y, Fu H, Ghosh S, et al. (2004). Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res 10:7382–91.
   PubMed Web of Science ®Google Scholar
• Zugazagoitia J, Guedes C, Ponce S, et al. (2016). Current challenges in cancer treatment. Clin Ther 38:1551–66.
   PubMed Web of Science ®Google Scholar
• Zuo YY, Uspal WE, Wei T. (2020). Airborne transmission of COVID-19: aerosol dispersion, lung deposition, and virus–receptor interactions. ACS Nano 14:16502–24.
   PubMed Web of Science ®Google Scholar